Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.7102
+0.0102 (1.46%)
At close: May 4, 2026, 4:00 PM EDT
0.7025
-0.0077 (-1.08%)
Pre-market: May 5, 2026, 6:56 AM EDT
Citius Pharmaceuticals Employees
Citius Pharmaceuticals had 23 employees as of September 30, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$171,483
Profits / Employee
-$1,560,280
Market Cap
19.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 23 | 0 | - |
| Sep 30, 2024 | 23 | 1 | 4.55% |
| Sep 30, 2023 | 22 | 1 | 4.76% |
| Sep 30, 2022 | 21 | 6 | 40.00% |
| Sep 30, 2021 | 15 | 5 | 50.00% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
| Genenta Science | 9 |
| Allarity Therapeutics | 8 |
| Exicure | 8 |
CTXR News
- 5 days ago - Citius Oncology Ships First International Order of LYMPHIR™ to Europe - PRNewsWire
- 10 days ago - Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 10 days ago - What's Behind The Drop In Citius Pharmaceuticals? - Benzinga
- 10 days ago - Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PRNewsWire
- 5 weeks ago - Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - PRNewsWire
- 7 weeks ago - Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PRNewsWire
- 2 months ago - Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - PRNewsWire